EQT Life Sciences’ EQT Health Economics 3 Fund Receives £25 Million Commitment from British Business Bank to Fuel UK Healthtech Innovation

The British Business Bank has announced a significant commitment of £25 million to EQT Life Sciences’ EQT Health Economics 3 Fund (EQT HE3), a multi-stage fund dedicated to life sciences and medtech. This substantial investment underscores the UK government’s strategic focus on bolstering its high-potential life sciences sector, identified as a key growth area within the UK Industrial Strategy. The commitment signifies a strengthened partnership between the British Business Bank and EQT Life Sciences, building upon their shared history of co-investments in pioneering UK healthtech companies.

EQT Life Sciences, renowned for its deep expertise and extensive track record spanning three decades, has successfully raised over £3.7 billion across 13 private funds. The firm has a distinguished history of nurturing over 150 companies, guiding them from early-stage clinical development through to successful commercialization. EQT HE3 specifically targets commercial-stage, de-risked medtech and digital health technologies that are demonstrably driving innovation and transforming the delivery of healthcare services. This strategic alignment between the fund’s mandate and the British Business Bank’s objectives is poised to accelerate the growth of promising UK-based healthtech ventures.

The British Business Bank’s investment in EQT HE3 is not an isolated initiative but a continuation of its broader mission to support the UK’s vibrant life sciences ecosystem. This sector is a cornerstone of the UK’s economy, contributing significantly to research, development, and job creation. The government recognizes the critical role of specialist investors in scaling these complex and capital-intensive businesses. By channeling investment into high-quality international funds like EQT HE3, the British Business Bank aims to attract further capital into the UK, ensuring that British companies benefit from the expertise and financial backing of leading global investors.

A Deeper Dive into the Partnership and its Significance

This latest commitment represents a significant deepening of the relationship between the British Business Bank and EQT Life Sciences. The Bank has previously demonstrated its confidence in EQT’s investment acumen through co-investments in two notable UK healthtech companies. In 2023, the Bank participated in Phagenesis’ $42 million Series D funding round. Phagenesis is a medical technology company focused on developing innovative solutions for dysphagia, a swallowing disorder that affects millions worldwide. More recently, in 2025, the Bank co-invested in Cyted Health’s $44 million Series B funding round. Cyted Health is an innovative diagnostics startup aiming to revolutionize early cancer detection through advanced technology. These prior collaborations highlight a shared vision for supporting companies at the forefront of medical innovation and a proven track record of successful partnership.

The strategic focus of EQT HE3 on commercial-stage, de-risked technologies is particularly noteworthy. This approach suggests a strategy aimed at supporting companies that have moved beyond the initial research and development phases and are demonstrating tangible market traction or have a clear path to commercialization. Such a focus can provide crucial capital and strategic guidance to companies that are ready to scale their operations, expand their market reach, and ultimately deliver their innovative solutions to patients and healthcare providers.

Drew Burdon, Partner at EQT Life Sciences, articulated his enthusiasm for the continued collaboration. He stated, "Over recent years, we have built an excellent relationship with The Bank through co-investments in leading UK health tech companies. The Bank’s investment will further contribute to our commitment to tap into the attractive UK health tech ecosystem and grow strong companies together." This statement emphasizes the mutual respect and shared objectives that characterize the partnership. Burdon’s words highlight EQT’s strategic intent to leverage the UK’s robust healthtech landscape and its desire to foster the growth of companies within it, with the British Business Bank serving as a key enabler of this ambition.

Christine Hockley, Managing Director and Head of Commercial Equity Funds at the British Business Bank, echoed this sentiment, underscoring the UK’s position as a global leader in life sciences. She remarked, "The UK is home to a world-class life sciences sector, but scaling companies in the sector requires specialist investors. By investing in high-quality international funds, we encourage greater investment to flow back into the UK and ensure UK companies benefit from the capital and expertise of leading investors." Hockley’s statement provides crucial insight into the British Business Bank’s strategy. It acknowledges the inherent challenges in scaling life sciences companies, which often require substantial capital and specialized knowledge. The Bank’s approach of investing in reputable international funds like EQT Life Sciences is a deliberate tactic to bridge this gap, acting as a catalyst for increased private sector investment and ensuring that UK companies gain access to both financial resources and invaluable strategic insights from experienced global players.

Supporting Data: The UK Life Sciences Sector in Numbers

The UK life sciences sector is a significant contributor to the national economy, characterized by its strong research base, innovative companies, and substantial investment. According to the Office for Life Sciences, the sector is one of the UK’s largest and most successful industries, generating an estimated £89 billion in turnover annually and employing over 500,000 people. The UK consistently ranks among the top global destinations for life sciences investment, attracting significant venture capital and private equity funding.

In 2023, the UK’s medtech sector alone saw substantial investment, with companies raising over £1.2 billion across more than 100 deals, according to data from Beauhurst. This trend highlights the increasing investor confidence in the sector’s potential for growth and innovation. Digital health, in particular, has witnessed exponential growth, driven by advancements in artificial intelligence, data analytics, and remote patient monitoring technologies. The global digital health market is projected to reach hundreds of billions of dollars in the coming years, with the UK well-positioned to capture a significant share of this market.

The UK Industrial Strategy has identified eight key growth sectors, with life sciences being one of the most prominent. This strategic prioritization translates into various government initiatives aimed at fostering innovation, supporting research and development, and creating an environment conducive to investment and business growth. The British Business Bank, as the UK’s economic development bank, plays a pivotal role in this strategy by de-risking investment and encouraging private sector capital to flow into these crucial sectors.

Chronology of Key Events and Relationships

The partnership between the British Business Bank and EQT Life Sciences has been cultivated over time, marked by strategic co-investments that demonstrate a shared commitment to advancing UK healthtech.

• Establishment of EQT Life Sciences: EQT Life Sciences has a history of over 30 years in the life sciences investment arena, building a robust portfolio and a reputation for successful company development.
• UK Industrial Strategy: The UK government identifies life sciences as a key growth sector, signaling its strategic importance and commitment to its development.
• Previous Co-investments:
  • 2023: British Business Bank co-invests in Phagenesis’ $42 million Series D funding round. This demonstrates an early engagement with EQT’s portfolio companies in the UK.
  • 2025 (reported): British Business Bank co-invests in Cyted Health’s $44 million Series B funding round. This recent co-investment signifies continued confidence in EQT’s investment strategy and the potential of UK healthtech startups.
• September 2, 2025 (reported): EQT Life Sciences’ EQT Health Economics 3 Fund receives a £25 million commitment from the British Business Bank. This latest announcement marks a significant escalation of the partnership.
• EQT HE3 Fund Focus: The fund targets commercial stage, de-risked medtech and digital health technologies, indicating a strategic shift towards supporting companies ready for scaling and market penetration.

Broader Impact and Implications

The £25 million commitment from the British Business Bank to EQT HE3 is more than just a financial transaction; it represents a strategic endorsement of the UK’s life sciences sector and its potential for global impact. This investment is expected to have several significant implications:

• Accelerated Innovation: By providing crucial capital and strategic expertise to commercial-stage healthtech companies, EQT HE3, backed by the British Business Bank, will enable these businesses to accelerate their product development, expand their market reach, and bring life-changing innovations to patients faster.
• Enhanced UK Competitiveness: The investment reinforces the UK’s position as an attractive destination for life sciences investment, encouraging further domestic and international capital to flow into the sector. This influx of funding can foster a more competitive and dynamic ecosystem, driving further innovation and economic growth.
• Job Creation and Economic Growth: The growth of these high-potential companies will inevitably lead to job creation across various disciplines, from research and development to manufacturing, sales, and marketing, contributing to the UK’s overall economic prosperity.
• Leveraging Global Expertise: EQT Life Sciences, as an international investor, brings not only capital but also global market insights, operational expertise, and a vast network of contacts. This infusion of international experience can significantly benefit UK companies, helping them navigate global markets and achieve international success.
• Validation of Digital Health and Medtech: The fund’s specific focus on commercial-stage, de-risked medtech and digital health technologies highlights the growing investor confidence in these sub-sectors. This validation can encourage further investment and innovation in areas such as AI-driven diagnostics, remote patient monitoring, and personalized medicine.
• Alignment with Industrial Strategy: The British Business Bank’s investment directly supports the UK Industrial Strategy’s objective of building a world-leading life sciences sector. This alignment ensures that public and private investment efforts are coordinated to maximize impact and achieve strategic national goals.

In conclusion, the £25 million commitment from the British Business Bank to EQT Life Sciences’ EQT HE3 fund is a pivotal development for the UK’s healthtech and life sciences sectors. It signifies a strong vote of confidence in the sector’s future, a deepening of a valuable partnership, and a clear commitment to fostering innovation and economic growth within the UK. The strategic focus of EQT HE3 on commercial-stage, de-risked technologies ensures that this investment will likely translate into tangible advancements in healthcare delivery and improved patient outcomes, solidifying the UK’s position as a global leader in life sciences innovation.